Veracyte Balance Sheet Health
Financial Health criteria checks 6/6
Veracyte has a total shareholder equity of $1.1B and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $1.2B and $81.4M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | n/a |
Cash | US$209.19m |
Equity | US$1.12b |
Total liabilities | US$81.42m |
Total assets | US$1.20b |
Recent financial health updates
No updates
Recent updates
Veracyte, Inc.'s (NASDAQ:VCYT) Price Is Right But Growth Is Lacking
Jun 06Veracyte, Inc. (NASDAQ:VCYT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
May 09Lacklustre Performance Is Driving Veracyte, Inc.'s (NASDAQ:VCYT) Low P/S
Apr 18A Look At The Intrinsic Value Of Veracyte, Inc. (NASDAQ:VCYT)
Mar 18Veracyte Percepta Genomic Sequencing Classifier demonstrates accuracy in lung cancer risk
Jul 13Veracyte: Not A Healthy Diagnosis
May 12Financial Position Analysis
Short Term Liabilities: VCYT's short term assets ($290.4M) exceed its short term liabilities ($58.1M).
Long Term Liabilities: VCYT's short term assets ($290.4M) exceed its long term liabilities ($23.4M).
Debt to Equity History and Analysis
Debt Level: VCYT is debt free.
Reducing Debt: VCYT has no debt compared to 5 years ago when its debt to equity ratio was 15.3%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable VCYT has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: VCYT is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 35% per year.